Skip to content

Stephanie E. Daws

Temple University

2 papers in the library · 19 citations · publishing 2024-2025

Papers

Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats

Molecular Psychiatry October 21, 2024 Gabriele Floris, Mary Tresa Zanda, Konrad Dabrowski et al. 19 citations

A single dose of psilocybin given to rats 4–24 hours before a relapse test reduced cue-induced heroin seeking, though it did not alter actual heroin taking. Blocking the serotonin 2A receptor with antagonists worsened relapse. Psilocybin regulated about twice as many genes in the prefrontal cortex at a higher dose, with ketanserin blocking over 90% of these gene changes, including the IL-17a cytokine receptor. Psilocybin also regulated four chemokine/cytokine genes, and selectively inhibiting IL-17a in the prefrontal cortex was enough to reduce heroin relapse. The findings suggest psilocybin reduces heroin relapse and point to IL-17a signaling as a possible downstream pathway.

Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats

Behavioural Pharmacology September 25, 2025 Saadet Inan, Paige E. Morris, Scott M. Rawls et al.

Psilocybin, the active compound in Psilocybe mushrooms, reduced pain-related behaviors in adult male rats exposed to formalin-induced noxious stimuli, a model of both acute and persistent inflammatory pain. Doses of 0.1 and 0.3 mg/kg significantly decreased flinching and licking during both early and late pain phases. Pretreatment with volinanserin, a selective blocker of the 5-HT 2A receptor, eliminated this pain-relieving effect, indicating that psilocybin produces analgesia at least partly by activating that receptor.